InHouse Medical LLC

12/14/2025

Interesting medical insight I came across this week:
There’s new research suggesting that semaglutide, a medication commonly used for type 2 diabetes and weight management, may be linked to a much lower risk of developing adult-onset epilepsy in people with diabetes. The reduction was around 50 percent compared to other diabetes medications.

What stood out to me is that this effect didn’t seem to be explained by better blood sugar control or weight loss alone. That points toward a possible direct benefit on brain health, not just metabolism.

We’ve already seen data showing GLP-1 medications may have protective effects in conditions like stroke and dementia. This adds another layer to the conversation and suggests there may be something unique going on in the brain when these medications are used.

One physician involved in the discussion mentioned that for patients with type 2 diabetes who also have a higher risk of seizures, semaglutide could be worth considering with overall brain health in mind, not just cardiovascular or glucose outcomes.

This is still early research and not medical advice, but it’s a good reminder that these medications are more complex than the weight loss headlines make them seem. The more we learn, the clearer it becomes that metabolic health and brain health are deeply connected.

Always interesting to watch where science goes next.


Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes - Medscape - December 10, 2025

12/07/2025

New Research Alert: Certain Medications May Increase the Risk of PCOS

Polycystic O***y Syndrome (PCOS) affects millions of women worldwide. Still, a new large-scale study just uncovered something important: some commonly used medications may be linked to an increased risk of developing PCOS-like symptoms.

Using over 10 years of data from the FDA Adverse Event Reporting System (FAERS), researchers reviewed more than 1,500 cases. They identified 18 medications that showed a significant association with PCOS-related side effects.

Here’s what the study found:

• Medications most often linked to PCOS risk included certain antipsychotics, anticonvulsants, steroid-based inhalers, bronchodilators, hormonal agents, and even some antiviral drugs.
• The strongest signals were seen with Mecasermin, Ciclesonide, Valproic Acid, and Olanzapine.
• PCOS symptoms tended to appear either within the first 30 days of starting a medication or after long-term use (over 1 year).
• Women ages 20–39 reported the highest number of medication-related PCOS cases.

Why does this matter?
PCOS is not just about irregular periods — it’s linked to infertility, metabolic issues, diabetes, heart disease, and chronic inflammation. Understanding which medications may affect hormonal balance helps healthcare providers choose safer treatments and monitor patients more closely.

What this study doesn’t claim:
It does not say these drugs cause PCOS.
It does not recommend stopping any prescribed medication.
It does highlight the need for awareness, monitoring, and more research.

The Bottom Line:
This is the first large study to systematically analyze medications linked to PCOS symptoms across millions of FDA reports. It’s a reminder that women's health deserves deeper research — especially when it comes to how medications may influence hormones and long-term health.

If you or someone you know is taking medications for asthma, seizures, mental health, or chronic illness and has symptoms like irregular cycles, acne, weight changes, or hair growth, talk to your healthcare provider about whether medication could be playing a role.

Your health story matters — and studies like this help all of us make more informed decisions.
Data summarized from a large-scale analysis of the FDA Adverse Event Reporting System (FAERS), 2014–2024, examining potential medication associations with polycystic o***y syndrome (PCOS).

www.InHouseMedicine.com

We accept insurance. Obtain your Wegovy and Zepbound if you qualify from the pharmacy.

11/16/2025

New Research: Tirzepatide Shows Powerful Weight-Loss Results for Women with PCOS

At InHouse Medical, we stay on top of the latest science so you can feel confident in your care. The newest data on Tirzepatide for women with PCOS is big news.

A real-world analysis of over 4,200 women with PCOS, overweight, or obesity found significant weight loss with Tirzepatide treatment:

-Average weight loss of 18.8% in just 10 months
-Women who engaged with coaching, tracking, and digital support lost even more, over 21%
-Over 96% lost at least 5% of their body weight, and 90% lost 10% or more

PCOS affects up to 1 in 10 women and often makes weight loss incredibly challenging. These results highlight the effectiveness of Tirzepatide when paired with consistent support and guidance.

While further research is needed on biomarkers and symptom improvement, this represents a significant step forward in helping women manage PCOS, insulin resistance, and long-term metabolic health.

Semaglutide is another highly effective option for weight loss and insulin resistance — and many women with PCOS respond exceptionally well to it. Both medications work on similar pathways, but Tirzepatide combines two hormone receptors for potentially stronger results.

If you’re struggling with PCOS or weight that won’t budge, you’re not alone, and you have options.

Send us a message to see if Tirzepatide/semaglutide could be right for you.

Cite this: Tirzepatide Significantly Lowers Weight in Women With PCOS - Medscape - November 13, 2025.

’sHealth

11/10/2025

U.S. Food and Drug Administration (FDA) is initiating the removal of broad “black box” warnings from HRT (hormone replacement Therapy) products for menopause.

"As women go through menopause, the ovaries produce less estrogen and progesterone. FDA-approved HRT containing estrogen and progesterone (or estrogen alone as indicated for postmenopausal women without a uterus) can restore these declining hormones and relieve symptoms such as hot flashes, night sweats, sleep disturbances, and bone loss."

Randomized studies show that women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures. Women may also reduce their risk of cardiovascular diseases by as much as 50%, Alzheimer’s disease by 35%, and bone fractures by 50 to 60%.

The FDA is NOT seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products.

The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health.

10/27/2025

Testosterone Therapy: Unlocking Better Health, Strength, and Vitality—No Added Heart or Cancer Risk

A comprehensive meta-analysis covering studies up to July 2025 confirms that testosterone replacement therapy improves libido, erectile function, lean mass, bone density, and insulin sensitivity—without increasing the risk for major cardiovascular events or prostate cancer when patients are appropriately monitored.

Erythrocytosis continues to be the most frequent side effect observed, highlighting the importance of regular follow-up during therapy.
www.inhousemedicine.com
(Source: Testosteron Replacement Therapy in Men Aged 50 and Above, September 2025. NIH PMC)

Call now to connect with business.

10/24/2025

Testosterone therapy in men with diabetes and hypogonadism may reduce risks of kidney injury, cardiovascular events, and mortality. The study suggests considering testosterone as a potential intervention for renal protection in this population.

Testosterone Protects Renal Health in Men With Diabetes - Medscape - October 09, 2025.

If you’re interested in Testosterone therapy come check us out.
Inhousemedicine.com/testosterone

We accept insurance. Obtain your Wegovy and Zepbound if you qualify from the pharmacy.

10/19/2025

Semaglutide: Targeting Fat While Protecting Muscle

At InHouse Medical, we focus on more than just weight loss, we focus on helping you lose fat while keeping your strength.

A recent study published in Diabetes, Obesity and Metabolism found that people using once-weekly semaglutide (2.4 mg) for 12 months lost a significant amount of body fat while preserving lean muscle mass and even improving muscle strength.

Here’s what researchers discovered:
✅ Average weight loss: 12.7% after one year
✅ Fat mass decreased by nearly 19%
✅ Muscle strength improved (handgrip up by 4 kg)
✅ Metabolism increased, supporting long-term results

These findings show that semaglutide doesn’t just change the scale, it supports a healthier body composition and stronger, more efficient metabolism.

At InHouse Medical, we use this research-based approach to help our patients achieve lasting success while maintaining their energy and strength.

Learn more or schedule your consultation today at InHouseMedicine.com

Source: MEDBRIEF “Semaglutide Targets Fat While Protecting Muscle Mass,” edited by Shrabasti Bhattacharya, October 17, 2025. Published in Diabetes, Obesity and Metabolism.

10/18/2025

Menopause isn’t just about hot flashes, it can change how your body stores fat, builds muscle, and handles stress.
As estrogen levels drop, women may face what experts call a “triple whammy”:
• More insulin resistance
• Less muscle mass (slower metabolism)
• Higher cortisol from sleep disruption

Add in mood shifts, life stress, and new aches and pains (“musculoskeletal syndrome of menopause”), and it’s easy to see why weight loss gets harder.

At InHouse Medical, we help women navigate this transition with medically guided strategies that address hormones, metabolism, and mindset, not just calories.

Located in Waterbury, CT
Telehealth and in-office visits available
www.Inhousemedicine.com

09/30/2025

The Hidden Pillar of Weight Control: Why Sleep Matters!

You already know that healthy eating and regular exercise are essential for effective weight management. But what if we told you there's a third, equally powerful pillar that many of us are neglecting? Sleep!

Emerging research, including findings noted by the American Heart Association, confirms that insufficient sleep isn't just about feeling tired, it's strongly linked to an increased risk of obesity, diabetes, and heart disease.

The Sleep-Weight Connection:
-Appetite Hormones: Poor sleep can disrupt the hormones that regulate your appetite, making you feel hungrier and less satisfied.

-Insulin Sensitivity: It can reduce your body's sensitivity to insulin.

-Cravings: It makes it harder to resist high-calorie, "comfort" foods.

-Reduced Energy: Lack of sleep means less physical activity, slowing your metabolism.

One study found that sleeping less than 7 hours nearly doubled the rate of overweight and obesity!

1. Be Consistent: Stick to a regular sleep schedule, even on weekends.

2. Power Down: Limit use of electronic devices (phones, tablets, TV) close to bedtime, as the blue light suppresses sleep-inducing melatonin.

3. Wind Down: Create a relaxing routine like reading a book, taking a warm bath, or listening to soft music.

4. Set the Scene: Keep your bedroom dark, quiet, and cool.

Your weight-loss journey, energy levels, and overall health will thank you!

Call now to connect with business.

09/28/2025

New warning label changes for Tylenol coming:
The FDA has started the process of updating warning labels on acetaminophen (Tylenol and similar products). New studies suggest that using acetaminophen during pregnancy may be linked to a higher chance of children later being diagnosed with conditions like autism or ADHD.

It’s important to know:
• Researchers have found an association, but this does not prove cause and effect.
• Some studies show this possible link, while others do not.
• In many cases, acetaminophen may still be the safest option for treating fevers during pregnancy. Untreated high fevers can also be dangerous for moms and babies.
• Other pain relievers, like aspirin and ibuprofen, are already known to cause problems in pregnancy.

What this means: Pregnant women should talk with their doctors before using acetaminophen. While many may choose to avoid it for mild discomfort or low-grade fevers, there are still times when it may be reasonable and necessary.

The FDA’s goal is to make sure parents and providers have the information they need to make the safest choice.

Disclaimer: This post is for informational purposes only and should not be taken as medical advice. Always consult your healthcare provider about your specific situation.

U.S. Food and Drug Administration. (2025, September 22). FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy [Press release]. U.S. Food and Drug Administration.

The .gov means it’s official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

09/01/2025

STAY AWAY FROM ULTRA-PROCESSED FOODS
A groundbreaking study from the University of Copenhagen reveals that ultra-processed foods contribute to fat gain, lower testosterone levels, and even introduce harmful chemicals— all WITHOUT increasing calorie intake.

👉 Men in the study gained more fat on processed foods compared to whole foods, even when calories, protein, carbs, and fats were identical.
👉 Hormones took a hit: testosterone and fertility markers dropped.
👉 Pollutants from packaging and processing were found in their bodies—linked to declining s***m quality.

At InHouse Medical, we see every day how diet, hormones, and health are connected. This research confirms what we emphasize with our patients: it’s not just about calories—it’s about the quality of your food.

If you’re struggling with weight gain, low energy, or hormone imbalance, our team can help you get answers through advanced lab testing and personalized treatment plans.

Visit us in Waterbury, CT, or schedule a telehealth consult today.

Learn more about our services at www.inhousemedicine.com

Source: University of Copenhagen. Why ultra-processed diets make you gain fat even without extra calories. ScienceDaily, August 30, 2025.

Call now to connect with business.

08/27/2025

Patients who are overweight or obese may have a lower risk of developing cancer if they take GLP-1 receptor agonists, according to research published in JAMA Oncology.
Researchers found that patients taking GLP-1 receptor agonists had a lower risk of cancer overall as well as lower risks of meningioma, endometrial cancer, and ovarian cancer.
This study is limited by its observational nature and by the lack of longitudinal assessments of BMI. Therefore, it’s not clear whether the apparent reduction in cancer risk was due to the GLP-1 receptor agonists themselves or the drug-induced weight loss.
www.inhousemedicine.com
https://www.cancertherapyadvisor.com/news/glp-1-receptor-agonists-risk-cancers/?utm_source=eloqua&utm_medium=email&utm_campaign=NWLTR_CTA_UPDT_RSS_LI-LAS1-LAS2-DI_10043_082725_RM&hmemail=T0Ku8v0kKjuqauKTZn2Npd%2FfndfC6gdj&sha256email=89a228e077dac9fd41f63b15e834e3fdad119dd46633442bc228d678c67266a1&hmsubid=jPmb3cqhEhw%3D&nid=1033414867&elqtrack=True

Patients taking GLP-1 receptor agonists had a lower risk of cancer overall as well as lower risks of certain cancers.